U.S.-based clinical-stage biopharmaceutical company Turning Point Therapeutics has raised over $166 million in its stock market listing.
Turning Point's initial public offering has seen greater demand than expected that the company priced its shares at the top the range and put more shares on sale.
The company is expected to use the proceeds from the offering to further its preclinical operations and for the development of its drugs.
Turning Point will list on the Nasdaq exchange under the stock symbol TPTX.